Zoetis Inc. (NYSE:ZTS) issued an update on its FY17 earnings guidance on Thursday morning. The company provided EPS guidance of $2.34-$2.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.34. The company issued revenue guidance of $5.225-$5.275 billion, compared to the consensus revenue estimate of $5.20 billion.
Shares of Zoetis Inc. (NYSE:ZTS) traded up $3.94 during mid-day trading on Friday, hitting $68.46. The stock had a trading volume of 2,697,292 shares, compared to its average volume of 2,443,592. The company has a market cap of $32,799.38, a P/E ratio of 30.88 and a beta of 1.02.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a return on equity of 66.15% and a net margin of 18.29%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.52 earnings per share. analysts predict that Zoetis Inc. will post 2.36 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be issued a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Wednesday, November 8th. Zoetis’s payout ratio is presently 22.11%.
Several analysts have recently commented on ZTS shares. Stifel Nicolaus restated a buy rating and set a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. Deutsche Bank AG restated a buy rating and set a $65.00 target price (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Cowen and Company set a $70.00 target price on Zoetis and gave the stock a buy rating in a report on Monday, July 17th. Cantor Fitzgerald reiterated a buy rating and issued a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. Finally, Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the company a buy rating in a report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $65.76.
TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/11/03/zoetis-inc-zts-issues-fy17-earnings-guidance.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.